Head-to-head · WeighScore
Mint Med vs Found
The verdict
Mint Med takes it — 84/100 to 82/100, but only just.
Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states. Found is close behind and may still be the better fit — see the factor split below.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Mint Med | Found |
|---|---|---|
| WeighScore | 84/100 | 82/100 |
| Grade | B | B− |
| Scorecard rank | #15 | #19 |
| Semaglutide | $117/mo | $129/mo |
| Tirzepatide | $159/mo | $129/mo |
| Coverage | 36 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #15 · B
Strengths
- $117 sema / $159 tirz
- LegitScript-verified
- Both molecules
Where it loses points
- Only 36 states
- Injection-only
- Monitoring detail sparse
Graded #19 · B−
Strengths
- Low identical pricing on both molecules
- Nationwide
- Strong coaching
Where it loses points
- Subscription coaching model isn't for everyone
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.